Company · founded 2007
Forma Therapeutics (United States)
Watertown, United States · formatherapeutics.com
- Citations, last 5 years
- 601
- Works, last 5 years
- 27
- h-index
- 83
- Scientists listed
- 3
- Grants since 2016
- 11
Grants received
2025–2027 · research · R44
A Novel Platelet-Inspired Nanotechnology to Restore Hemostasis in Patients on Antiplatelet Agents
Ujjal Didar Singh Sekhon · Forma Therapeutics (United States) · funded by National Institutes of Health
2025 · research · R44
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia
Michael Arthur Bruckman · Forma Therapeutics (United States) · funded by National Institutes of Health
2021–2022 · research · R43
A novel monoclonal antibody-based anti-NK cell anti-inflammatory strategy for treating autoimmune and checkpoint inhibitor induced myocarditis
Dror Luger · Forma Therapeutics (United States) · funded by National Institutes of Health
2020–2022 · grant · Standard Grant
SBIR Phase II: Manufacturing and Characterization of a Synthetic Platelet (SynthoPlateTM) Technology
Michael Bruckman · Forma Therapeutics (United States) · funded by National Science Foundation
2019–2025 · research · R44
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia
Michael Arthur Bruckman · Forma Therapeutics (United States) · funded by National Institutes of Health
2019–2025 · research · R44
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia
Michael Arthur Bruckman · Forma Therapeutics (United States) · funded by National Institutes of Health
2019–2020 · research · R43
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia
Michael Arthur Bruckman · Forma Therapeutics (United States) · funded by National Institutes of Health
2019–2025 · research · R44
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia
Michael Arthur Bruckman · Forma Therapeutics (United States) · funded by National Institutes of Health
2018–2019 · grant · Standard Grant
SBIR Phase I: Manufacturing and Characterization of a Synthetic Platelet (SynthoPlateTM) Technology
Christa Pawlowski · Forma Therapeutics (United States) · funded by National Science Foundation
2018 · research · Research Grant
Developing New Drugs that Deactivate Deubiquitinase Proteins for the Treatment of Parkinson's Disease
Stephanos Ioannidis · Forma Therapeutics (United States) · funded by Michael J. Fox Foundation for Parkinson's Research
2017 · research · Therapeutic Pipeline Program
Protein Homeostasis and the Ubiquitination Pathway in Parkinson's Disease
Stephanos Ioannidis · Forma Therapeutics (United States) · funded by Michael J. Fox Foundation for Parkinson's Research